Furthermore, it is possible that the addition of a third agent that is able to modulate the tumor microenvironment may be an effective strategy to potentiate the response to the combined anti-angiogenic and PD-1/PD-L1 blockade in ccRCC. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.